SMT201400117B - Glyx-13 per l'uso in un metodo di trattamento della depressione refrattaria - Google Patents

Glyx-13 per l'uso in un metodo di trattamento della depressione refrattaria

Info

Publication number
SMT201400117B
SMT201400117B SM201400117T SM201400117T SMT201400117B SM T201400117 B SMT201400117 B SM T201400117B SM 201400117 T SM201400117 T SM 201400117T SM 201400117 T SM201400117 T SM 201400117T SM T201400117 B SMT201400117 B SM T201400117B
Authority
SM
San Marino
Prior art keywords
glyx
treatment method
refractory depression
depression treatment
refractory
Prior art date
Application number
SM201400117T
Other languages
English (en)
Italian (it)
Inventor
Joseph Moskal
Original Assignee
Univ Northwestern
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Northwestern filed Critical Univ Northwestern
Publication of SMT201400117B publication Critical patent/SMT201400117B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Glass Compositions (AREA)
  • Compositions Of Oxide Ceramics (AREA)
  • Ceramic Products (AREA)
SM201400117T 2009-10-05 2014-08-19 Glyx-13 per l'uso in un metodo di trattamento della depressione refrattaria SMT201400117B (it)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24865009P 2009-10-05 2009-10-05
PCT/US2010/051415 WO2011044089A2 (en) 2009-10-05 2010-10-05 Methods of treating depression and other related diseases

Publications (1)

Publication Number Publication Date
SMT201400117B true SMT201400117B (it) 2014-11-10

Family

ID=43857351

Family Applications (1)

Application Number Title Priority Date Filing Date
SM201400117T SMT201400117B (it) 2009-10-05 2014-08-19 Glyx-13 per l'uso in un metodo di trattamento della depressione refrattaria

Country Status (12)

Country Link
EP (4) EP2485751B1 (xx)
CY (1) CY1118530T1 (xx)
DK (2) DK2985032T3 (xx)
ES (2) ES2493316T3 (xx)
HR (1) HRP20140784T1 (xx)
HU (1) HUE043807T2 (xx)
PL (2) PL2985032T3 (xx)
PT (2) PT2985032T (xx)
RS (1) RS53513B1 (xx)
SI (1) SI2485751T1 (xx)
SM (1) SMT201400117B (xx)
WO (1) WO2011044089A2 (xx)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2331571B1 (en) 2008-09-18 2015-08-26 Northwestern University Nmda receptor modulators and uses thereof
US8951968B2 (en) 2009-10-05 2015-02-10 Northwestern University Methods of treating depression and other related diseases
SG10201811584RA (en) 2010-02-11 2019-01-30 Univ Northwestern Secondary Structure Stabilized NMDA Receptor Modulators And Uses Thereof
KR101692275B1 (ko) * 2010-02-11 2017-01-04 노오쓰웨스턴 유니버시티 ２차 구조 안정화된 ｎｍｄａ 수용체 조절제 및 그의 용도
US9737531B2 (en) 2012-07-12 2017-08-22 Glytech, Llc Composition and method for treatment of depression and psychosis in humans
US10583138B2 (en) 2012-07-12 2020-03-10 Glytech, Llc Composition and method for treatment of depression and psychosis in humans
SG10202010665YA (en) * 2011-04-27 2020-11-27 Univ Northwestern Methods of treating alzheimer's disease, huntington's disease, autism, or other disorders
WO2014059326A2 (en) * 2012-10-12 2014-04-17 Northwestern University Methods of identifying compounds for treating depression and other related diseases
CA2898863A1 (en) 2013-01-29 2014-08-07 Naurex, Inc. Spiro-lactam nmda receptor modulators and uses thereof
AU2014212485C1 (en) 2013-01-29 2018-10-25 Aptinyx, Inc. Spiro-lactam NMDA receptor modulators and uses thereof
HUE043843T2 (hu) 2013-01-29 2019-09-30 Aptinyx Inc Spiro-laktám NMDA receptor modulátorok és azok alkalmazása
AU2014212501A1 (en) 2013-01-29 2015-07-30 Aptinyx, Inc. Spiro-lactam NMDA receptor modulators and uses thereof
EA201591404A1 (ru) 2013-01-29 2016-01-29 Аптиникс Инк. Спиролактамные модуляторы рецептора nmda и их применение
MX2016007716A (es) * 2013-12-13 2017-03-31 Univ Northwestern Metodos para el tratamiento de trastornos cerebrales o la identificacion de biomarcadores relacionados con estos.
CN105327349A (zh) * 2014-06-18 2016-02-17 上海翰森生物医药科技有限公司 Nmda受体拮抗剂的医药用途及其药物组合物
KR20170018072A (ko) * 2014-06-23 2017-02-15 노오쓰웨스턴 유니버시티 편두통을 치료 또는 경감시키는 방법
SG11201701134XA (en) * 2014-08-14 2017-03-30 Naurex Inc Methods of treating depression using nmda modulators
CA3002070A1 (en) * 2015-10-16 2017-04-20 Northwestern University Pharmaceutical combination of an atypical antipsychotic and an nmda modulator for the treatment of schizophrenia,bipolar disorder, cognitive impairment and major depressive disorder
WO2017189920A1 (en) * 2016-04-28 2017-11-02 The Trustees Of The University Of Pennsylvania Method of drug design and optimisation utilizing stereochemical mimicry
WO2017201285A1 (en) 2016-05-19 2017-11-23 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
CA3024606C (en) 2016-05-19 2019-09-03 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
BR112019001768A2 (pt) 2016-08-01 2019-06-11 Aptinyx Inc moduladores do receptor de spiro-lactamas nmda e usos dos mesmos
BR112019001926A2 (pt) 2016-08-01 2019-08-06 Aptinyx Inc moduladores do receptor nmda espiro-lactama e bis-espiro-lactama e usos destes
CA3031534C (en) 2016-08-01 2023-10-17 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
JP7032378B2 (ja) 2016-08-01 2022-03-08 アプティニックス インコーポレイテッド スピロ－ラクタムｎｍｄａ受容体修飾因子及びその使用
EP3490990B1 (en) 2016-08-01 2023-12-06 Tenacia Biotechnology (Hong Kong) Co., Limited Spiro-lactam nmda modulators and methods of using same
WO2019152687A1 (en) 2018-01-31 2019-08-08 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4086196A (en) 1975-03-28 1978-04-25 Armour Pharmaceutical Company Parathyroid hormone
US5763393A (en) 1996-05-17 1998-06-09 Neurotherapeutics L.P. Neuroactive peptides
US20030065138A1 (en) * 2001-03-07 2003-04-03 University Of Utah Research Foundation Linear gamma-carboxyglutamate rich conotoxins
WO2002072609A2 (en) * 2001-03-12 2002-09-19 Nyxis Neurotherapies, Inc Neuroactive peptides for prevention and/or treatment of hypoxia and neuropathic pain
WO2005014797A2 (en) * 2003-08-08 2005-02-17 The Burnham Institute P16 mediated regulation of nmda receptors
US20050096311A1 (en) * 2003-10-30 2005-05-05 Cns Response Compositions and methods for treatment of nervous system disorders

Also Published As

Publication number Publication date
EP2485751B1 (en) 2014-05-21
EP2485751A4 (en) 2013-03-13
WO2011044089A3 (en) 2012-02-16
EP2485751A2 (en) 2012-08-15
EP2985032B1 (en) 2019-01-02
RS53513B1 (en) 2015-02-27
HUE043807T2 (hu) 2019-09-30
ES2493316T3 (es) 2014-09-11
CY1118530T1 (el) 2017-07-12
DK2985032T3 (en) 2019-04-15
ES2721448T3 (es) 2019-07-31
PT2485751E (pt) 2014-09-01
HRP20140784T1 (hr) 2014-10-10
PL2985032T3 (pl) 2019-07-31
SI2485751T1 (sl) 2014-10-30
WO2011044089A2 (en) 2011-04-14
DK2485751T3 (da) 2014-08-18
EP2985032A1 (en) 2016-02-17
PT2985032T (pt) 2019-04-24
EP2813236A1 (en) 2014-12-17
EP3488856A1 (en) 2019-05-29
PL2485751T3 (pl) 2014-10-31

Similar Documents

Publication Publication Date Title
SMT201400117B (it) Glyx-13 per l'uso in un metodo di trattamento della depressione refrattaria
GB0607088D0 (en) Vaccine
IL193566A0 (en) Hpv-18-based papillomavirus vaccine
EP2313553A4 (en) ART STONE
BR112012004593A2 (pt) "método"
IL193661A0 (en) Papillomavirus vaccine
GB0616306D0 (en) Vaccines
HK1129836A1 (zh) 疫苗
EP2013546A4 (en) LIFT
GB0614460D0 (en) Vaccines
ZA200901592B (en) Vaccine
GB0625593D0 (en) Vaccine
HUP0900280A2 (en) Portable rail scale
GB0614962D0 (en) Complex for use in vaccines
ZA200808893B (en) HPV-16-Based Papillomavirus vaccine
GB0608962D0 (en) Vaccine
GB0614476D0 (en) Vaccine
GB0620815D0 (en) Vaccine
GB0620337D0 (en) Vaccine
GB0619826D0 (en) Vaccine
GB0614254D0 (en) Vaccine
GB0606256D0 (en) Anti-atheroma vaccine
GB0620336D0 (en) Vaccine
GB0607087D0 (en) Vaccine
GB0620816D0 (en) vaccine